Regeneron Pharmaceuticals (REGN) Change in Acquisitions & Divestments (2009 - 2026)

Regeneron Pharmaceuticals has reported Change in Acquisitions & Divestments for 18 years, with the latest figure at $2.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 24.63% year-over-year to $2.6 billion; the trailing twelve-month figure through Mar 2026 stood at $10.7 billion (down 25.49% YoY), and the FY2025 full-year result was $11.5 billion, down 23.17% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $2.6 billion, up from $2.6 billion in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $4.3 billion in Q3 2024, with the low at $746.3 million in Q1 2022.
• Average Change in Acquisitions & Divestments over 5 years is $2.6 billion, with a median of $2.6 billion recorded in 2025.
• Year-over-year, Change in Acquisitions & Divestments soared 383.46% in 2022 and plunged 46.53% in 2025.
• Tracing REGN's Change in Acquisitions & Divestments over 5 years: stood at $1.5 billion in 2022, then soared by 55.0% to $2.4 billion in 2023, then increased by 8.36% to $2.6 billion in 2024, then declined by 1.05% to $2.6 billion in 2025, then climbed by 2.02% to $2.6 billion in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $2.6 billion (Q1 2026), $2.6 billion (Q4 2025), and $3.4 billion (Q3 2025), per Business Quant data.

Peer Comparison